# Ne oldu?

The Turkish Social Security Institution (SGK) announced on Friday that it has added two medications for Hemophilia B and one cancer drug to its reimbursement list. One of the three newly covered products is locally produced. In the same announcement, SGK said it raised the reimbursement rate for magistral (compounded) drugs dispensed by pharmacies by 40 percent. Additionally, the scope of coverage was expanded for pediatric surgical procedures and for patients awaiting bone‑marrow‑transplant procedures, including updated donor‑screening protocols.

# Ayrıntılar

According to the official statement, the two Hemophilia B drugs join existing therapies on the list, offering patients more options for a genetic bleeding disorder that requires lifelong treatment. The cancer medication added is not specified by name in the announcement but is described as a new inclusion in SGK’s oncology portfolio. The 40 percent increase in magistral drug reimbursement is intended to ease the financial burden on pharmacies and patients who rely on customized formulations. Coverage expansions for pediatric surgeries and bone‑marrow‑transplant procedures are part of SGK’s broader effort to improve access to specialized care for children and patients with hematologic conditions.

# Neden önemli?

These updates directly affect thousands of patients managing chronic conditions. The inclusion of locally produced Hemophilia B drugs may reduce dependence on imports and lower long‑term costs. The 40 percent boost to compounded‑drug reimbursement addresses a frequent complaint from pharmacies about thin margins on customized prescriptions. Expanding pediatric surgical and transplant coverage improves access to life‑saving interventions that were previously partially out‑of‑pocket for families. Overall, the moves signal SGK’s continued focus on rare‑disease and oncology affordability.

# Sırada ne var?

No immediate follow‑up statements have been issued. Patients and pharmacists are advised to check the updated SGK reimbursement portal for exact drug names, coverage percentages, and any new documentation requirements. Future announcements may detail pricing adjustments or additional inclusions in the next SGK board meeting.